SCHEMBL2260767

SCHEMBL2260767

NC(=O)Cc1cnc(Cl)c2ccoc12

nearest known ligand 0.35

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 1/20 0.33
CA2 P00918 1/20 0.33
KCNA2 P16389 2/20 0.32
KCNA5 P22460 2/20 0.32
KCNA1 Q09470 2/20 0.32
KCNA4 P22459 1/20 0.32
KCNH2 Q12809 1/20 0.32
MAPT P10636 1/20 0.32
KCNA3 P22001 1/20 0.32
PLA2G2A P14555 1/20 0.31
CFD P00746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2264336 0.80 ALOX5 (0.32) PLA2G10KCNA2KCNA5KCNA1KCNA3
SCHEMBL30753228 0.73 LMNA (0.40) KCNA3
SCHEMBL29196588 0.73 LMNA (0.40) KCNA3
SCHEMBL2262714 0.72 ICMT (0.36) PLA2G10CA2MAPT
SCHEMBL30753213 0.72 KCNA3 (0.37) KCNA2KCNA5KCNA1KCNA4KCNH2
SCHEMBL2262353 0.72 CFD (0.36) PLA2G10CA2CFD
SCHEMBL29196587 0.72 KCNA3 (0.37) KCNA2KCNA5KCNA1KCNA4KCNH2
SCHEMBL24126871 0.72
SCHEMBL2262537 0.70 ICMT (0.35) PLA2G10CA2CFD
SCHEMBL30110634 0.70 CASP3 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110294792-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2011-12-01 US disclosed
US-8058425-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2011-11-15 US disclosed
US-8022065-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20110207721-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2011-08-25 US disclosed
US-20090105229-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY 2009-04-23 US disclosed
US-7491716-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2009-02-17 US disclosed
EP-1483265-B1 PURINE DERIVATIVES AS KINASE INHIBITORS LILLY CO ELI (US) 2006-11-22 EP disclosed
US-20050090483-A1 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY 2005-04-28 US disclosed
EP-1483265-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2004-12-08 EP disclosed
WO-2003076442-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090483-A1 Purine derivatives as kinase inhibitors PNP, ADK, NME2 PLA2G10 3409/4885CA2 2659/4885KCNA2 3089/4885
US-20110294792-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 PLA2G10 3409/4885CA2 2659/4885KCNA2 3089/4885
US-20110207721-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 PLA2G10 3409/4885CA2 2659/4885KCNA2 3089/4885
US-20090105229-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 PLA2G10 3409/4885CA2 2659/4885KCNA2 3089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.